1-8 of 8
Debasmita Roy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

Free
Krish Patel, Matthew Lunning, Konstantinos Sdrimas, Minoo Battiwalla, Uttam Rao, Yi Lin, Sami Ibrahimi, Jennifer L. Crombie, Sairah Ahmed, Iris Isufi, Matthew Frigault, David Bernasconi, Debasmita Roy, Marcelo Pasquini, Bradley D. Hunter
Journal: Blood
Blood (2025) 146 (Supplement 1): 5482.
https://doi.org/10.1182/blood-2025-5482
Published: 2025
Journal Articles

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Free
Sahar Ansari, Manali Kamdar, Eniko Papp, Mazyar Shadman, Jeremy Abramson, Begüm D. Topçuoglu, Pei Yang, Lara Stepan, Pradipta Ray, Amanda Przespolewski, Krishna R. Juluri, Eric Bleickardt, Debasmita Roy, Alessandro Crotta, Timothy B. Campbell, Julie A. Rytlewski, Abood Okal, Ethan Thompson, Leanne Peiser
Journal: Blood
Blood (2025) 146 (Supplement 1): 1775.
https://doi.org/10.1182/blood-2025-1775
Published: 2025
Journal Articles

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study

Free
Pradipta Ray, Abood Okal, Miguel-Angel Perales, Sandeep Raj, Roni Shouval, Eniko Papp, Sahar Ansari, Krishna R. Juluri, Amanda Przespolewski, Debasmita Roy, Ethan Thompson, Julie A. Rytlewski, Eric Bleickardt, Alessandro Crotta, Timothy B. Campbell, Leanne Peiser
Journal: Blood
Blood (2025) 146 (Supplement 1): 3549.
https://doi.org/10.1182/blood-2025-3549
Published: 2025
Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Free
Sairah Ahmed, Avyakta Kallam, Matthew Frigault, Bradley D. Hunter, Sagar S. Patel, David Bernasconi, Soyoung Kim, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Marcelo C. Pasquini, Jennifer L. Crombie
Journal: Blood
Blood (2024) 144 (Supplement 1): 472.
https://doi.org/10.1182/blood-2024-199702
Published: 2024
Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Free
Maria Silvina Odstrcil Bobillo, Swetha Kambhampati, Dasom Lee, Bradley D. Hunter, Ogechukwu Egini, Krish Patel, Patrick M. Reagan, David Bernasconi, Soyoung Kim, Charimar Santiago Parrilla, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Sairah Ahmed, Jennifer L. Crombie, Saurabh Dahiya, Mehdi Hamadani, Catherine J. Lee, Marcelo C. Pasquini, Mazyar Shadman, Alex F. Herrera, Matthew Frigault
Journal: Blood
Blood (2024) 144 (Supplement 1): 470.
https://doi.org/10.1182/blood-2024-199723
Published: 2024
Journal Articles

Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines

Free
e-blood
Debasmita Roy, Sang-Hoon Sin, Blossom Damania, Dirk P. Dittmer
Journal: Blood
Blood (2011) 118 (7): e32–e39.
https://doi.org/10.1182/blood-2010-12-323659
Published: 2011
Includes: Supplemental data
Journal Articles

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas

Free
Aadra P. Bhatt, Prasanna M. Bhende, Sang-Hoon Sin, Debasmita Roy, Dirk P. Dittmer, Blossom Damania
Journal: Blood
Blood (2010) 115 (22): 4455–4463.
https://doi.org/10.1182/blood-2009-10-251082
Published: 2010
Includes: Supplemental data
Journal Articles

Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling

Free
Sang-Hoon Sin, Debasmita Roy, Ling Wang, Michelle R. Staudt, Farnaz D. Fakhari, Dhavalkumar D. Patel, David Henry, William J. Harrington, Jr, Blossom A. Damania, Dirk P. Dittmer
Journal: Blood
Blood (2006) 109 (5): 2165–2173.
https://doi.org/10.1182/blood-2006-06-028092
Published: 2006
Includes: Supplemental data